Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for
the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney
disease on hemodialysis as measured by time to death.